

REMARKS

Status of claims.

Claims 21-26 and 35 are pending in the application. With entry of the instant amendment, claim 21 has been amended. The amendment adds no new matter and is supported by the specification as filed. Claim 21 has been amended to recite that the xenograft simulates the progression from androgen-dependence to androgen-independence.

Support can be found, *e.g.*, specification page 10, lines 4-10.

Rejections under 35 U.S.C. § 102

Claims 21-23 and 26 were rejected as allegedly anticipated by Crowley *et al.*, *PNAS, USA*, 90: 5021-5025 (1993); claims 21, 22, 24 and 26 were rejected as allegedly anticipated by Monosov *et al.*, in U.S. Patent 5,491,284; and claims 21, 22, 26 and 35 were rejected as allegedly anticipated by Stearn and Wang, *Cancer Research* 52: 3778-3781 (1992). In order to expedite prosecution, claim 21 has been amended to recite that the xenograft simulates progression from androgen-dependence to androgen-independence. As the examiner knows, in order for a reference to anticipate a pending claim, it must provide, either expressly or implicitly, all claim limitations (see, *e.g.*, MPEP §2131). None of the cited references teach a model of prostate cancer that simulates disease progression from androgen-dependence to androgen-independence. Accordingly, the claims are patentable over the cited art.

Claim 25

Claim 25 was rejected as being dependent on a rejected base claim. This rejection is obviated by the amendment to claim 21. Applicants therefore respectfully request its withdrawal.

Appl. No. 10/022,115
Amdt. dated October 6, 2005
Reply to Office Action of July 15, 2005

PATENT

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:ds
60597985 v1